Bioavailability of 2 Different Nevirapine Extended Release Formulations Compared to Viramune® in HIV-1 Infected Subjects
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective was to establish the pharmacokinetic (PK) profile at steady state of two
different nevirapine (NVP) extended release (XR) formulations at 300 mg or 400 mg daily (QD)
under fasted and fed conditions in comparison with the commercially available NVP immediate
release (IR) tablet at 200 mg BID (400 mg/day).